Table 4 Annual cost, annual health benefits and cost-effectiveness ratio of selected CVD interventions in Ethiopia
From: Prevention and treatment of cardiovascular disease in Ethiopia: a cost-effectiveness analysis
Intervention description | Annual cost in million US$ | Annual DALYs averted (discounted) | Annual DALYs averted (undiscounted) | ACER | ICER |
|---|---|---|---|---|---|
Acute myocardial infarction | |||||
 ACE-inhibitor | 2.37 | 316 | 422 | 7531 | Dominated |
 Beta-blocker | 2.38 | 586 | 784 | 4057 | Dominated |
 ASA | 2.38 | 990 | 1325 | 2200 | Dominated |
 Streptokinase | 2.82 | 1170 | 1566 | 2408 | Dominated |
 ASA + clopidogrel | 2.38 | 1441 | 1927 | 1556 | Dominated |
 ASA + streptokinase | 2.84 | 2110 | 2822 | 1295 | Dominated |
 ASA + streptokinase + ACE-inhibitor | 2.85 | 2396 | 3205 | 1149 | Dominated |
 Primary PCI | 8.29 | 2747 | 3675 | 3013 | Dominated |
 ASA + streptokinase + ACE-inhibitor + beta-blocker | 2.92 | 2919 | 3905 | 999 | 999 |
 ASA + clopidogrel + PCI | 8.5 | 4015 | 5370 | 2115 | 5087 |
Acute stroke | |||||
 ASA | 2.53 | 63 | 80 | 39,892 | 39,892 |
Post-acute IHD | |||||
 ASA | 2.54 | 245 | 330 | 10,345 | Dominated |
 Statin | 2.74 | 310 | 417 | 8822 | Dominated |
 Beta-blocker | 2.53 | 488 | 657 | 5177 | Dominated |
 ACE-inhibitor | 2.55 | 524 | 705 | 4857 | Dominated |
 ASA + beta-blocker | 2.57 | 732 | 985 | 3511 | Dominated |
 ASA + beta-blocker + statin | 2.82 | 1038 | 1397 | 2717 | Dominated |
 ASA + beta-blocker + statin + ACE-inhibitor | 2.88 | 1557 | 2096 | 1849 | 1849 |
Post-acute stroke | |||||
 ACE-inhibitor | 2.87 | 912 | 1200 | 3153 | Dominated |
 ASA | 2.86 | 1013 | 1348 | 2821 | Dominated |
 Statin | 3.30 | 1375 | 1813 | 2396 | Dominated |
 ASA + statin | 3.40 | 2382 | 3150 | 1428 | Dominated |
 ASA + statin + ACE-inhibitor | 3.48 | 3284 | 4337 | 1061 | 1061 |
Primary prevention of IHD and stroke | |||||
 Cholesterol lowering treatment for total chol. >6.2 mmol/l | 4.67 | 8768 | 15,913 | 532 | Dominated |
 Cholesterol lowering treatment for total chol. >5.7 mmol/l | 10.62 | 19,073 | 34,143 | 557 | Dominated |
 Anti-hypertension treatment for SBP >160 mmHg | 7.33 | 98,880 | 172,868 | 74 | Dominated |
 Combination drug treatment for absolute risk of CVD >35 % | 7.18 | 107,687 | 185,249 | 67 | 67 |
 Anti-hypertension treatment for SBP >140 mmHg | 19.42 | 125,712 | 220,992 | 154 | Dominated |
 Combination drug treatment for absolute risk of CVD >25 % | 9.83 | 127,957 | 219,230 | 77 | 131 |
 Combination drug treatment for absolute risk of CVD >15 % | 14.41 | 153,877 | 263,747 | 94 | 177 |
 Combination drug treatment for absolute risk of CVD >5 % | 26.85 | 190,391 | 329,117 | 141 | 341 |